TNFSF13B and systemic lupus erythematosus: Alternative immunotherapies target the ligand of BAFFR, BAFF, which exists in multiple forms, including membrane-bound, soluble trimer, and 60-mer forms.10 In 2011, the US Food and Drug Administration approved a blocking antibody against soluble BAFF as treatment in systemic lupus erythematosus patients.